Linda Schneider
Family Medicine · Hampton, VANPI 1699711242
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (41.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Merck at 31.0% of the total. Among family medicine clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 199 payments — averaging $47.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$3K
- AstraZeneca$3K
- Boehringer Ingelheim$2K
- Amgen$595
- Lilly USA, LLC$278
- Novo Nordisk$266
- plus $1K from 21 others
Across 1,321 payments — averaging $1595.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$799K
- Boehringer Ingelheim Pharma GmbH & Co.kg$229K
- Amgen$214K
- Novartis$162K
- Boehringer Ingelheim International GmbH$149K
- Akebia Therapeutics Inc$133K
- plus $421K from 7 others
What the payments were for
- Consulting fees$1,71518%
- Travel & lodging$3,95241%
- Food & beverage$3,83940%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 18 | $2,950 |
| AstraZeneca | 32 | $2,509 |
| Boehringer Ingelheim | 24 | $1,904 |
| Amgen | 33 | $595 |
| Lilly USA, LLC | 20 | $278 |
| Novo Nordisk | 13 | $266 |
| GSK | 12 | $231 |
| Pfizer | 8 | $121 |
| Johnson & Johnson(2 entities) | 7 | $102 |
| AbbVie | 5 | $98 |
| Akebia Therapeutics Inc | 1 | $70 |
| Amarin Pharma, Inc. | 4 | $50 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| Aurinia Pharma U.S., Inc. | 2 | $32 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| Avanir Pharmaceuticals, Inc. | 2 | $27 |
| Mallinckrodt Enterprises LLC | 1 | $24 |
| UCB, Inc. | 1 | $21 |
| Radius Health, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Novartis | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $11 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,525 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amlodipine Besylate | 11 | $103 |
| Furosemide | 12 | $23 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Hampton
- Oluwaronke AwosikaFort Gregg Adams$397K
- Monique MatuskowitzNorfolk$110K
- Paul StairsRichmond$105K
- Edwin RobinsonRichmond$83K
- Benjamin PhilpottRocky Mount$64K
- John MolaiyArlington$64K
- Catherine VarneyZion Crossroads$47K
- Jordan TranWinchester$42K
- John ClayColonial Heights$40K
- Thomas RobesonNewport News$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.